Ipsen Aims To Dominate In Botulinum Toxins With Syntaxin Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Watch out Allergan; Ipsen says it has ambitions to become the world leader in recombinant botulinum toxins after announcing plans to acquire UK-based Syntaxin.